Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.49 (reverse transcriptase)
 31,746 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Delavirdine (Rescriptor) is available through an expanded access program. Pharmacia & Upjohn's non-nucleoside reverse transcriptase inhibitor works in combination with AZT to reduce viral loads and increase CD4 counts. Effects are sustained for as long as a year. Its most common side effect is rash.
 ...
PMID:Expanded access for delavirdine. 1136 26

The Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee recommended the accelerated approval of nevirapine, a nonnucleoside reverse transcriptase inhibitor. The recommendation was based on immunologic and virologic data obtained in several trials. Nevirapine must be given in combination with nucleoside analogs. Combining protease inhibitors with nevirapine is being considered, but more data on its safety is necessary. HIV becomes resistant to nevirapine, but curiously, some patients sustain their reduction in HIV RNA. Several adult nevirapine trials are summarized. Pediatric studies have shown interesting results, such as effective entry of the drug into both plasma and cerebrospinal fluid, decreased viral load, and antibody seroreversion. The primary side effect of nevirapine is rash, which may be fatal in some patients.
 ...
PMID:Nevirapine: new drug, new class, new questions. 1136 50

Now available in pharmacies, the first of a new class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been licensed. Nevirapine (marketed as Viramune) is different from nucleoside reverse transcriptase inhibitors because it binds at a different location on the HIV-1 virus and at a different point in the reproduction process in its effort to block HIV replication. Also, HIV-1 mutant strains, which become resistant to other drugs, have remained sensitive to nevirapine. The Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee recommended that nevirapine be used only in combination therapy, but did not complicate the label by stating whether to include one or two additional drugs. They recommended approval for both treatment-naive and experienced individuals. Although suppression of viral replication is modest, the NNRTIs appear to penetrate the central nervous system and offer an alternative for people either intolerant of or resistant to the currently available nucleoside analogs. A major side effect of the drug is the development of a severe rash. The manufacturer, Boehringer Ingelheim, has promised to issue a booklet on how to manage a nevirapine-related rash. Individuals interested in the patient assistance program may call Boehringer Ingelheim for more information.
 ...
PMID:Nevirapine, the first of a new class of NNRTI drugs arrives in pharmacies. 1136 27

The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) for HIV-1 treatment in March. Delavirdine becomes the second non-nucleoside reverse transcriptase inhibitor approved; the first was nevirapine. The drug must be used in antiretroviral combinations because of resistance problems associated with using it alone. Delavirdine's primary side effect is skin rash, occasionally severe enough to cause permanent discontinuation of the treatment. The approval follows weak clinical data; further clinical testing is called for. Cost is relatively low at $2,250 annually.
 ...
PMID:Delavirdine (Rescriptor) approved. 1136 52

Delavirdine (Rescriptor), a non-nucleoside reverse transcriptase inhibitor, has received Food and Drug Administration (FDA) approval. Delavirdine has been studied in combination with other antiretrovirals in more than 2,400 patients. The drug is well tolerated, with skin rash being the most common side effect. The annual cost of treatment with Rescriptor is $2,250, with some minimal discounts available through AIDS Drug Assistance Programs.
 ...
PMID:Delavirdine gets FDA approval. Food and Drug Administration. 1136 63

Results from a clinical trial of 718 participants, 139 of them women, indicate that women experience 1.8 times higher concentrations of delavirdine (Rescriptor) than do men. Women's smaller body size increases the dose per kilogram ratio compared to men, although pharmacokinetic studies have not demonstrated a gender difference in metabolism. The main side effect caused by delavirdine, a non-nucleoside reverse transcriptase inhibitor produced by Pharmacia and Upjohn, is a temporary rash that disappears without changing the treatment.
 ...
PMID:Delavirdine levels in women. 1136 81

DuPont Merck is conducting clinical trials of its new non-nucleoside reverse transcriptase inhibitor, DMP 266, at more than 100 hospitals. The drug is the first anti-HIV medication to be taken only once a day, and it shows significant viral load decreases when taken in combination with indinavir. Side effects include rash, sinusitis, upper respiratory infection, and diarrhea. Enrollment information is included. Merck will announce an expanded access program in September 1997.
 ...
PMID:DMP 266 on the horizon. 1136 36

Four new drugs have been developed to overcome the limitations of the currently available anti-HIV drugs, including inconvenient schedules, side effects, and drug interactions. It is hoped that abacavir, efavirenz, adefovir dipivoxil, and amprenavir will be widely available in the near future. Abacavir, a nucleoside reverse transcriptase inhibitor with a twice-daily schedule, offers good bioavailability and generally mild side effects. Efavirenz, a non-nucleoside reverse transcriptase inhibitor with a once daily schedule, may produce side effects such as rash and dizziness. Adefovir dipivoxil, a nucleotide analog with once daily dosing, can cause carnitine depletion and carnitine supplementation is recommended. Amprenavir, a protease inhibitor with twice-daily dosing, has rather mild side effects. Information on efficacy, availability, and resistance for each of these drugs is given.
 ...
PMID:Antiretroviral agents: the next generation. 1136 27

Phase III data show that efavirenz (Sustiva, formerly DMP-266) is effective in suppressing viral load when used in combination with other treatments. A head-to-head comparison trial in volunteers with little or no previous antiretroviral experience shows that efavirenz may suppress viral load as well as Indinavir (Crixivan). Efavirenz is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI), and widespread consensus seems to accept it as a valid treatment for AIDS. The most noteworthy trial result showed that using it in combination with AZT plus 3TC suppressed viral load to below 400 copies in a significant number of volunteers, with few patients dropping out. Viral load remains low at 72 weeks, but not much information is available on those patients who were more heavily pre-treated. Other combinations also appear effective. DuPont Pharmaceuticals, the manufacturer, says common side effects include rash, nausea, diarrhea, headache, and insomnia, and cautions against widespread use in pregnant women. Efavirenz is unlikely to work in patients who have developed resistance to either Nevirapine or Delavirdine, two other NNRTI drugs.
 ...
PMID:Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination. 1136 99

The Food and Drug Administration (FDA) approved DuPont Pharma's new non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, DMP-266). Efavirenz has shown promise in trials with over 2000 participants for up to 24 weeks, and early data suggests it may be as effective as protease inhibitors when used in a combination regimen. It is the first anti-HIV drug approved for once-daily dosing. Efavirenz is well tolerated, and the main side effects reported are dizziness, insomnia, abnormal dreams, and skin rash. Efavirenz has been approved for adults and children, but should not be used by pregnant women. Contact information is provided.
 ...
PMID:FDA approves efavirenz. Food and Drug Administration. 1136 87


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>